Downgrade
| ShowHide Related Items >><< - 07/15/22
- Coupang rises 7.9%
- 07/01/22
- Coupang rises 13.4%
- 07/01/22
- Coupang rises 9.1%
- 05/12/22
- Coupang rises 24.8%
- 06:39 Today Mizuho
- Coupang price target raised to $22 from $18 at Mizuho
- 08/10/22 Macquarie
- Macquarie started Coupang at Outperform with $26 target yesterday
- 08/09/22 Macquarie
- Coupang initiated with an Outperform at Macquarie
- 06/30/22 Credit Suisse
- Coupang upgraded to Outperform at Credit Suisse following underperformance
- 08/10/22
- Coupang raises FY22 adjusted EBITDA view
- 08/10/22
- Coupang reports Q2 EPS (4c), consensus (11c)
- 05/11/22
- Coupang reports Q1 EPS (12c), consensus (17c)
- 03/02/22
- Coupang sees 2022 adjusted EBITDA loss less than ($400M)
|
Hot Stocks
| ShowHide Related Items >><< - 09:26 Today
- Main Street trading halted, news pending
- 08/02/22
- Main Street raises dividend 2.3% to 66c
- 07/12/22
- Main Street invests $19.5M in three market portfolio companies
- 04/14/22
- Main Street originated $226.6M in new commitments in Q1
- 08/08/22 Raymond James
- Main Street downgraded to Market Perform from Outperform at Raymond James
- 03/07/22 Hovde Group
- Main Street initiated with a Market Perform at Hovde Group
- 11/11/21 Truist
- Main Street price target raised to $43 from $40 at Truist
- 11/08/21 Raymond James
- Main Street price target raised to $47 from $44 at Raymond James
- 08/04/22
- Main Street reports Q2 adjusted NII 78c, consensus 70c
- 05/05/22
- Main Street reports Q1 NII 77c, consensus 70c
- 02/24/22
- Main Street reports Q4 distribugtable NII 73c, consensus 65c
|
Hot Stocks
| ShowHide Related Items >><< - 09:39 Today
- Veru trading halted, volatility trading pause
- 08/09/22
- Veru announces presentation of phase 3 study of Sabizabulin
- 07/27/22
- Veru says EMA's ETF initiates review of sabizabulin for COVID-19 patients
- 07/25/22
- Veru announces UK's MHRA supports expedited review of MAA for sabizabulin
- 08/03/22 Oppenheimer
- Oppenheimer says analysis provides context on Veru COVID Phase 3 mortality rates
- 07/06/22 Jefferies
- Veru data likely portend FDA authorization in 30 days, says Jefferies
- 05/18/22 Brookline
- Veru price target raised to $31 from $29 at Brookline
- 05/13/22 Jefferies
- Veru price target raised to $55 from $33 at Jefferies
- 06:45 Today
- Veru reports Q3 EPS (28c), consensus (18c)
- 05/12/22
- Veru reports Q2 EPS (18c), consensus (15c)
- 07/08/22
- Culper Research says short Veru, sees ' little to no hope of' sabizabulin EUA
- 05/02/22
- Culper Research says shorting Veru, sees COVID-19 EUA as 'non-starter'
- 04/11/22
- STAT's Feuerstein asks how 45% mortality rate 'possible' in Veru placebo arm
- 07/08/22
- What You Missed On Wall Street On Friday
- 07/08/22
- What You Missed On Wall Street This Morning
- 07/06/22
- Fly Intel: After-Hours Movers
- 07/06/22
- What You Missed On Wall Street On Wednesday
- 07/07/22
- Veru call volume above normal and directionally bullish
- 06/27/22
- Veru call volume above normal and directionally bullish
- 06/07/22
- Veru call volume above normal and directionally bullish
- 06/07/22
- Unusually active option classes on open June 7th
|
Hot Stocks
| ShowHide Related Items >><< - 06:34 Today Stephens
- Alpha Teknova price target lowered to $15 from $22 at Stephens
- 10/14/21 Cowen
- Alpha Teknova price target raised to $30 from $24 at Cowen
- 08/10/22
- Alpha Teknova reports Q2 EPS (22c) vs. (52c) in last year's quarter
- 03/15/22
- Alpha Teknova sees FY22 revenue $44M-$48M, consensus $42.04M
- 03/15/22
- Alpha Teknova reports Q4 EPS (13c), consensus (17c)
- 02/28/22
- Alpha Teknova sees Q4 revenue $10-$10.1M, consensus $8.45M
|
Recommendations
|
Citi analyst P.J. Juvekar… ShowHide Related Items >><< - 08/04/22
- New Fortress Energy enters 120MW green hydrogen plant deal with Plug Power
- 08/04/22
- Plug Power selected by New Fortress Energy for 120 MW green hydrogen plant
- 07/29/22
- Microsoft posts blog detailing work with partner Plug Power
- 07/12/22
- Plug Power secures 5MW electrolyzer sale to Irving Oil
- 09:25 Today Truist
- Plug Power price target raised to $32 from $21 at Truist
- 08/10/22 B. Riley
- Plug Power price target raised to $32 from $31 at B. Riley
- 08/10/22 Cowen
- Plug Power price target lowered to $35 from $44 at Cowen
- 08/10/22 BMO Capital
- Plug Power price target raised to $29 from $20 at BMO Capital
- 08/09/22
- Plug Power reports Q2 EPS (30c) vs. (18c) last year
- 08/09/22
- Notable companies reporting after market close
- 05/09/22
- Plug Power reports Q1 EPS (27c), consensus (16c)
- 05/09/22
- Notable companies reporting after market close
- 08/09/22
- Fly Intel: After-Hours Movers
- 08/08/22
- What You Missed This Week in EVs and Clean Energy
- 06/13/22
- What You Missed This Week in EVs and Clean Energy
- 06/08/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/28/22
- Unusually active option classes on open July 28th
- 07/06/22
- Plug Power call volume above normal and directionally bullish
- 06/27/22
- Plug Power put volume heavy and directionally bearish
- 05/09/22
- Unusually active option classes on open May 9th
|
Hot Stocks
| ShowHide Related Items >><< - 09:37 Today
- Invitae trading halted, volatility trading pause
- 08/10/22
- Invitae rises 46.1%
- 08/08/22
- Cathie Wood's ARK Investment bought 813K shares of Invitae today
- 07/18/22
- Invitae announces strategic business realignment
- 08/10/22 JPMorgan
- Invitae cut to Underweight at JPMorgan with future growth yet to be proven
- 08/10/22 JPMorgan
- Invitae downgraded to Underweight from Neutral at JPMorgan
- 07/26/22 Cowen
- Invitae cut to Market Perform at Cowen on debt refinancing uncertainty
- 07/26/22 Cowen
- Invitae downgraded to Market Perform from Outperform at Cowen
- 08/09/22
- Invitae backs FY22 revenue growth of low double digits, consensus $542.96M
- 08/09/22
- Invitae reports Q2 adjusted EPS (68c), consensus (76c)
- 07/18/22
- Invitae sees second half of FY22 revenue flat over first half of FY22
- 07/18/22
- Invitae sees Q2 revenue $136M, consensus $142.74M
- 08/10/22
- What You Missed On Wall Street On Wednesday
- 08/10/22
- What You Missed On Wall Street This Morning
- 07/21/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/18/22
- Fly Intel: After-Hours Movers
- 08:00 Today
- Invitae call buyer realizes 3500% same-day gains
- 05/03/22
- Invitae options imply 14.1% move in share price post-earnings
- 02/24/22
- Invitae options imply 14.1% move in share price post-earnings
|
Periodicals
| ShowHide Related Items >><< - 06/09/22
- PPL Corp. increases common stock dividend to 22.5c from 20c per share
- 06/09/22
- PPL Corp. management to provide update on strategic financial targets
- 05/25/22
- PPL Corp. completes acquisition of Narragansett Electric from National Grid
- 05/23/22
- PPL says Rhode Island court clears way for Narragansett Electric acquisition
- 07/14/22 Mizuho
- PPL Corp. price target lowered to $29 from $30 at Mizuho
- 07/07/22 Evercore ISI
- PPL Corp. upgraded to Outperform at Evercore ISI with re-rating expected
- 07/07/22 Evercore ISI
- PPL Corp. upgraded to Outperform from In Line at Evercore ISI
- 06/07/22 Wells Fargo
- PPL Corp. price target raised to $34 from $33 at Wells Fargo
- 08/03/22
- PPL Corp. backs 2022 ongoing EPS view $1.30-$1.45, consensus $1.42
- 08/03/22
- PPL Corp. reports Q2 ongoing EPS 30c, consensus 29c
- 05/05/22
- PPL Corp. reports Q1 operating EPS 41c, consensus 39c
- 02/18/22
- PPL Corp. reports Q4 adjusted EPS 22c, consensus 32c
|
Hot Stocks
| ShowHide Related Items >><< - 08/09/22
- Veru announces presentation of phase 3 study of Sabizabulin
- 07/27/22
- Veru says EMA's ETF initiates review of sabizabulin for COVID-19 patients
- 07/25/22
- Veru announces UK's MHRA supports expedited review of MAA for sabizabulin
- 07/08/22
- Veru down 9% after Culper releases follow-up short report
- 08/03/22 Oppenheimer
- Oppenheimer says analysis provides context on Veru COVID Phase 3 mortality rates
- 07/06/22 Jefferies
- Veru data likely portend FDA authorization in 30 days, says Jefferies
- 05/18/22 Brookline
- Veru price target raised to $31 from $29 at Brookline
- 05/13/22 Jefferies
- Veru price target raised to $55 from $33 at Jefferies
- 06:45 Today
- Veru reports Q3 EPS (28c), consensus (18c)
- 05/12/22
- Veru reports Q2 EPS (18c), consensus (15c)
- 07/08/22
- Culper Research says short Veru, sees ' little to no hope of' sabizabulin EUA
- 05/02/22
- Culper Research says shorting Veru, sees COVID-19 EUA as 'non-starter'
- 04/11/22
- STAT's Feuerstein asks how 45% mortality rate 'possible' in Veru placebo arm
- 07/08/22
- What You Missed On Wall Street On Friday
- 07/08/22
- What You Missed On Wall Street This Morning
- 07/06/22
- Fly Intel: After-Hours Movers
- 07/06/22
- What You Missed On Wall Street On Wednesday
- 07/07/22
- Veru call volume above normal and directionally bullish
- 06/27/22
- Veru call volume above normal and directionally bullish
- 06/07/22
- Veru call volume above normal and directionally bullish
- 06/07/22
- Unusually active option classes on open June 7th
|
Conference/Events
| ShowHide Related Items >><< - 08/05/22
- FDA approves Bayer darolutamide tablets for prostate cancer
- 07/28/22
- Ionis Pharmaceuticals announces 'positive' results from Phase 2b RE-THINC ESRD
- 07/05/22
- Lyra Therapeutics appoints Nieman as Chief Medical Officer
- 06/28/22
- Bayer's Kerendia recives new grade A recommendations from ADA
- 07/20/22 Morgan Stanley
- Bayer price target raised to EUR 85 from EUR 83 at Morgan Stanley
- 06/13/22 Redburn
- FMC downgraded to Neutral on cost inflation at Redburn
- 05/19/22 UBS
- Bayer price target raised to EUR 96 from EUR 90 at UBS
- 05/11/22 Barclays
- Bayer price target raised to EUR 90 from EUR 85 at Barclays
- 08/04/22
- Bayer raises FY core EPS view to EUR7.30 vs. EUR7.00 previously
- 08/04/22
- Bayer reports Q2 core EPS EUR1.93 vs. EUR1.61 last year
- 05/10/22
- Bayer reports Q1 core EPS EUR 3.53 vs. EUR 2.59 last year
- 03/01/22
- Bayer sees 2022 group sales of EUR 47B
- 06/27/22
- Supreme Court lets $87M award against Bayer for Roundup stand, Bloomberg reports
- 06/21/22
- Supreme Court rejects Bayer bid to end Roundup suits, Bloomberg reports
- 05/11/22
- Biden administration asks Supreme Court to reject Roundup appeal, Reuters says
- 06/27/22
- What You Missed On Wall Street On Monday
- 06/27/22
- What You Missed On Wall Street This Morning
- 06/21/22
- What You Missed On Wall Street On Tuesday
- 06/21/22
- What You Missed On Wall Street This Morning
|
Hot Stocks
| ShowHide Related Items >><< - 08/10/22
- Invitae rises 46.1%
- 08/08/22
- Cathie Wood's ARK Investment bought 813K shares of Invitae today
- 07/18/22
- Invitae announces strategic business realignment
- 07/18/22
- Invitae says Kenneth Knight to succeed Sean George as CEO
- 08/10/22 JPMorgan
- Invitae cut to Underweight at JPMorgan with future growth yet to be proven
- 08/10/22 JPMorgan
- Invitae downgraded to Underweight from Neutral at JPMorgan
- 07/26/22 Cowen
- Invitae cut to Market Perform at Cowen on debt refinancing uncertainty
- 07/26/22 Cowen
- Invitae downgraded to Market Perform from Outperform at Cowen
- 08/09/22
- Invitae backs FY22 revenue growth of low double digits, consensus $542.96M
- 08/09/22
- Invitae reports Q2 adjusted EPS (68c), consensus (76c)
- 07/18/22
- Invitae sees second half of FY22 revenue flat over first half of FY22
- 07/18/22
- Invitae sees Q2 revenue $136M, consensus $142.74M
- 08/10/22
- What You Missed On Wall Street On Wednesday
- 08/10/22
- What You Missed On Wall Street This Morning
- 07/21/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/18/22
- Fly Intel: After-Hours Movers
- 08:00 Today
- Invitae call buyer realizes 3500% same-day gains
- 05/03/22
- Invitae options imply 14.1% move in share price post-earnings
- 02/24/22
- Invitae options imply 14.1% move in share price post-earnings
|